Rx-UNCY-2703 · March 25, 2027 sponsor target
Will the FDA approve Oxylanthanum carbonate for hyperphosphatemia in chronic kidney disease patients on dialysis?
Sponsor describes a nanoparticle oral phosphate binder and a March 25, 2027 target after NDA resubmission.
Open outcome workspaceA PDUFA goal date is not an approval determination or a trading cutoff. Application scope, delays and invalid-result terms require reviewed rules.
2 publications1 exact-program1 related2 context / correction notes
Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.
Sponsor describes a nanoparticle oral phosphate binder and a March 25, 2027 target after NDA resubmission.
Registry identifies an OLC tolerability study in dialysis patients sponsored by Unicycive.
This research candidate has no onchain question, committed rule hash or funded pool.
These terms require review and cannot resolve a market.
RESEARCH DRAFT / NOT FINAL RULES / NOT COMMITTED Program: Oxylanthanum carbonate Sponsor: Unicycive Therapeutics Indication under review: hyperphosphatemia in chronic kidney disease patients on dialysis Event: FDA marketing-approval decision Sponsor target: 2027-03-25 (date only, not a trading cutoff) YES: FDA approval of the exact application, formulation and eligible indication, established under a reviewed evidence hierarchy. Exact application/label scope requires review. NO: The approved market terms must specify treatment of a Complete Response Letter, withdrawal, extension and no decision by cutoff. No automatic NO outcome is inferred from the sponsor target date. INVALID: The approved terms must specify erroneous dates, ambiguous identity, unsupported evidence and withdrawal handling. No policy has been committed for this candidate. Cutoff and timezone: UNSET / OWNER APPROVAL REQUIRED. Evidence: FDA approval letter or other authoritative FDA record; sponsor disclosures require the corroboration specified in final rules. Oracle: assertion, dispute bond, liveness and final settlement require separately reviewed deployment settings. This draft cannot resolve a market or pay a claim. Publish reviewed canonical bytes and their keccak256 commitment before listing.
No question ID, approved deadline or UMA assertion exists for this research candidate. Sandbox claims have no redemption rights.